Veracyte Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
71,220.00
35,084.00
39,202.00
59,339.00
33,891.00
77,995
Total Accounts Receivable
1,143.00
3,050.00
3,503.00
8,956.00
12,716.00
13,168
Inventories
2,567.00
3,696.00
3,767.00
3,475.00
5,324.00
3,402
Other Current Assets
1,477.00
1,518.00
1,442.00
1,857.00
1,997.00
2,387
Total Current Assets
76,407.00
43,348.00
47,914.00
73,627.00
53,928.00
96,952
Net Property, Plant & Equipment
2,952.00
4,161.00
10,314.00
11,480.00
9,688.00
8,940
Total Investments and Advances
118.00
118.00
603.00
603.00
603.00
603
Intangible Assets
-
17,057.00
16,257.00
15,190.00
14,124.00
13,057
Other Assets
153.00
155.00
159.00
134.00
326.00
1,086
Total Assets
79,630.00
64,839.00
75,247.00
101,034.00
78,669.00
120,638
Accounts Payable
5,294.00
7,397.00
5,085.00
2,424.00
3,853.00
Other Current Liabilities
10,094.00
9,748.00
9,637.00
9,110.00
8,175.00
Total Current Liabilities
15,388.00
17,145.00
14,722.00
11,534.00
12,028.00
Long-Term Debt
4,899.00
4,923.00
4,990.00
25,517.00
25,246.00
Deferred Taxes
-
300.00
-
-
-
Other Liabilities
2,900.00
1,097.00
4,283.00
4,402.00
4,170.00
Total Liabilities
23,187.00
23,465.00
23,995.00
41,453.00
41,444.00
Common Equity (Total)
56,443.00
41,374.00
51,252.00
59,581.00
37,225.00
Total Shareholders' Equity
56,443.00
41,374.00
51,252.00
59,581.00
37,225.00
Total Equity
56,443.00
41,374.00
51,252.00
59,581.00
37,225.00
Liabilities & Shareholders' Equity
79,630.00
64,839.00
75,247.00
101,034.00
78,669.00

About Veracyte

View Profile
Address
6000 Shoreline Court
South San Francisco California 94080
United States
Employees -
Website http://www.veracyte.com
Updated 07/08/2019
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis.